IDH2 and glioblastoma: Thus, the identification of key wild-type IDH-mediated metabolic activity, depending on the genetic and metabolic landscape and involved in GBM aggressiveness, is a prerequisite for further development of specific wild-type IDH inhibitors in preclinical and clinical studies.